Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial (phase I closed to accrual as of 09/29/2009) is studying the side
effects and best dose of bortezomib, paclitaxel, and carboplatin when given with radiation
therapy and to see how well they work in treating patients with stage IIIA or stage IIIB
non-small cell lung cancer that cannot be removed by surgery. Bortezomib may stop the growth
of tumor cells by blocking the enzymes necessary for their growth. Drugs used in
chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells
from dividing so they stop growing or die. Bortezomib may increase the effectiveness of
paclitaxel and carboplatin by making tumor cells more sensitive to the drugs. Radiation
therapy uses high-energy x-rays to damage tumor cells. Giving bortezomib, paclitaxel, and
carboplatin together with radiation therapy may kill more tumor cells.